SignatureFD’s Direxion Daily S&P Biotech Bear 3X ETF LABD Stock Holding History

SignatureFD’s Portfolio LABD Stock Details LABD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-150	Closed	-$3.16K	–	3546
2025 Q4	$3.16K	Buy	+150	New	+$4.07K	﹤0.01%	2840

Other funds holding LABD

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

CCM

Capstone Capital Management Hong Kong $224M AUM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

SignatureFD's LABD Position: Q1 2026 in Review

SignatureFD sold out of Direxion Daily S&P Biotech Bear 3X ETF (LABD) in Q1 2026, closing a stake of 150 shares — an estimated $3.16K sold.

SignatureFD first reported a position in LABD in Q4 2025 and held it in 1 quarter. The position peaked at $3.16K in Q4 2025. 17 funds tracked by Wall St. Rank hold LABD as of Q1 2026.

SignatureFD reported no remaining Direxion Daily S&P Biotech Bear 3X ETF position as of Q1 2026 after selling out during the quarter.
SignatureFD sold 150 Direxion Daily S&P Biotech Bear 3X ETF shares in Q1 2026, an estimated $3.16K.
SignatureFD first reported a position in Direxion Daily S&P Biotech Bear 3X ETF in Q4 2025 and held it in 1 quarter.
SignatureFD's Direxion Daily S&P Biotech Bear 3X ETF position peaked at $3.16K in Q4 2025.
17 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bear 3X ETF as of Q1 2026.

Based on SignatureFD's 13F filing for Q1 2026, filed 7 Apr 2026.